[Antiarrhythmic properties of fubromegan on different models of experimental cardiac arrhythmia].
D031841:Aconitum / Q000037:antagonists & inhibitors; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D001281:Atrial Fibrillation / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D002122:Calcium Chloride / Q000037:antagonists & inhibitors; D002415:Cats; D002642:Chick Embryo; D046508:Culture Techniques; D004195:Disease Models, Animal; D004558:Electric Stimulation; D005730:Ganglionic Blockers / Q000627:therapeutic use*; D009206:Myocardium / Q000166:cytology; D011342:Procainamide / Q000627:therapeutic use*; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D051381:Rats; D013328:Strophanthins / Q000037:antagonists & inhibitors; D014693:Ventricular Fibrillation / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control
D000889:Anti-Arrhythmia Agents; D005730:Ganglionic Blockers; D000644:Quaternary Ammonium Compounds; D013328:Strophanthins; D011342:Procainamide; D002122:Calcium Chloride
Antiaritmicheskie svoĭstva fubromegana na razlichnykh modeliakh éksperimental'noĭ aritmii serdtsa.